0001209191-19-018307.txt : 20190311 0001209191-19-018307.hdr.sgml : 20190311 20190311080946 ACCESSION NUMBER: 0001209191-19-018307 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190308 FILED AS OF DATE: 20190311 DATE AS OF CHANGE: 20190311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nierenberg Michael CENTRAL INDEX KEY: 0001591719 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35777 FILM NUMBER: 19670965 MAIL ADDRESS: STREET 1: 1345 AVENUE OF THE AMERICAS CITY: NEW YORK STATE: NY ZIP: 10105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: New Residential Investment Corp. CENTRAL INDEX KEY: 0001556593 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 453449660 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1345 Avenue of the Americas CITY: New York STATE: NY ZIP: 10105 BUSINESS PHONE: 212-479-3195 MAIL ADDRESS: STREET 1: 1345 Avenue of the Americas CITY: New York STATE: NY ZIP: 10105 FORMER COMPANY: FORMER CONFORMED NAME: New Residential Investment LLC DATE OF NAME CHANGE: 20121214 FORMER COMPANY: FORMER CONFORMED NAME: Spinco Inc. DATE OF NAME CHANGE: 20120821 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-08 0 0001556593 New Residential Investment Corp. NRZ 0001591719 Nierenberg Michael 1345 AVENUE OF THE AMERICAS, 45 FL NEW YORK NY 10105 1 1 0 0 Chairman, CEO & President Stock Option (right to buy) 17.10 2019-03-08 4 A 0 500000 0.00 A 2028-01-19 Common Stock, par value $0.01 per share 500000 500000 D Stock Option (right to buy) 17.10 2019-03-08 4 A 0 75000 0.00 A 2028-01-23 Common Stock, par value $0.01 per share 75000 75000 D Stock Option (right to buy) 18.50 2019-03-08 4 A 0 2551 0.00 A 2028-08-23 Common Stock, par value $0.01 per share 2551 2551 D Stock Option (right to buy) 18.45 2019-03-08 4 A 0 236 0.00 A 2028-08-24 Common Stock, par value $0.01 per share 236 236 D Stock Option (right to buy) 18.54 2019-03-08 4 A 0 5000 0.00 A 2028-08-31 Common Stock, par value $0.01 per share 5000 5000 D Stock Option (right to buy) 18.57 2019-03-08 4 A 0 2046 0.00 A 2028-09-06 Common Stock, par value $0.01 per share 2046 2046 D Stock Option (right to buy) 17.32 2019-03-08 4 A 0 500000 0.00 A 2028-11-05 Common Stock, par value $0.01 per share 500000 500000 D Stock Option (right to buy) 17.32 2019-03-08 4 A 0 75000 0.00 A 2028-11-08 Common Stock, par value $0.01 per share 75000 75000 D Tandem awards correspond on a one-to-one basis with options granted to FIG LLC, the Company's manager (or an affiliate of the Company's manager), such that exercise by an employee of the tandem award would result in the corresponding option held by the manager being cancelled. Upon the grant of options to the manager (or an affiliate), such options are fully vested and become exercisable over a 30-month period (the "Total Exercisability Period") in equal monthly installments beginning on the first of each month following the month in which the options were granted. (Continued in Footnote 2) When tandem awards are granted with respect to manager options, the manager options become exercisable in equal monthly installments over a portion of the Total Exercisability Period equal to the product of (i) the ratio of manager options not subject to corresponding tandem options to the total number of manager options (including manager options underlying such tandem awards subject to corresponding tandem options) multiplied by (ii) 30 (such period, the "Manager Exercisability Period"). Following the Manager Exercisability Period, the tandem awards vest in generally equal monthly installments on the first of each month over the remainder of the Total Exercisability Period and become exercisable only at the end of the Total Exercisability Period. Represents the expiration date of the related manager option. In general, the expiration date of the tandem award occurs prior to the expiration date of the underlying option. Tandem awards will be settled in an amount of cash equal to the excess of the fair market value of a share of our common stock on the date of exercise over the fair market value on the date of grant, unless advance approval is given by the Board of Directors or an officer of the Company, as applicable, to settle the tandem awards in shares. /s/ Cameron MacDougall, as Attorney-in-Fact 2019-03-11